FIA
FATE icon

FNY Investment Advisers’s Fate Therapeutics FATE Stock Holding History

FNY Investment Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-828
Closed -$10K – 767
2018
Q4 		$10K Buy
+828
New +$11.5K ﹤0.01% 420

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

FNY Investment Advisers's FATE Position: Q1 2019 in Review

FNY Investment Advisers sold out of Fate Therapeutics (FATE) in Q1 2019, closing a stake of 828 shares — an estimated $10K sold.

FNY Investment Advisers first reported a position in FATE in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 123 funds tracked by Wall St. Rank hold FATE as of Q1 2019.

  • FNY Investment Advisers reported no remaining Fate Therapeutics position as of Q1 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 828 Fate Therapeutics shares in Q1 2019, an estimated $10K.
  • FNY Investment Advisers first reported a position in Fate Therapeutics in Q4 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Fate Therapeutics position peaked at $10K in Q4 2018.
  • 123 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2019.

Based on FNY Investment Advisers's 13F filing for Q1 2019, filed 17 Apr 2019.